The difference of recurrence of EGFR/ERBB2/MET is probably due to the different stage of tissues, as the majority data of MSKCC-IMPACT is from late-stage biopsy tissues; while TCGA NSCLC cohort, from early-stage lung cancer primary tumor tissues. Here, ERBB2 is linked to lung carcinoma.